ICU Medical is in the healthcare sector and medical instruments and equipment industry. The company CEO is Vivek Jain. ICU Medical Inc is engaged in the development, manufacture and sale of medical devices used in infusion therapy, oncology and critical care applications. Its products include needlefree connectors, nanoclave, chemoclock, chemoclave, and among others.
Previous Intraday Trading Performance:
The ICUI stock showed a previous change of 3.99% with an open at 216.32 and a close of 223.02. It reached an intraday high of 223.39 and a low of 216.32.
The stock has a market cap of $4.6b with 20.6m shares outstanding, of which the float is 20.0m shares. Trading volume reached 120,921 shares compared to its average volume of 200,620 shares. Based on the current average volume and close price, the trading liquidity is good.
Historical Trading Performance:
Over the last five trading days, ICU Medical shares returned 0.22% and in the past 30 trading days it returned -0.92%. Over three months, it changed -5.58%. In one year it has changed -24.01% and within that year its 52-week high was 321.70 and its 52-week low was 210.94. ICUI stock is 5.73% above its 52 Week Low.
Our calculations show a 200 day moving average of 247.98 and a 50 day moving average of 228.90. Currently ICUI stock is trading -10.06% below its 200 day moving average and may not be a good opportunity to buy as it may continue to trend down.
The last annual fiscal EPS for the company was reported at 1.34 that ended on 31st of December 2018, which according to the previous close, that is a PE of 166.43. Based on 2 analyst estimates, the consensus EPS for the next quarter is 1.96. The TTM EPS is 7.84, which comes to a TTM PE of 28.45. Historically, the PE high was 166.43 and the PE low was 20.50. If the stock reached its PE low, that would represent a price of 160.70, which is a decrease of -27.94%.
Below was the last reported quarterly diluted earnings per share:
|1st||Qtr of 2019||(Reported on 05/09/2019):||1.44|
|4th||Qtr of 2018||(Reported on 02/28/2019):||-0.36|
|3rd||Qtr of 2018||(Reported on 11/08/2018):||0.01|
|2nd||Qtr of 2018||(Reported on 08/09/2018):||1.44|
|1st||Qtr of 2018||(Reported on 05/09/2018):||0.23|
Base on our calculations, the intrinsic value per share is 262.15, which means it is possibly undervalued and has a margin of safety of 14.93%.
Indicators to Watch:
The current calculated beta is 0.72.
Based on last reported financials, the company’s return on equity is 4.57%, return on assets is 3.69%, profit margin is 4.09%, price-to-sales is 3.25 and price-to-book is 3.45.
All scores are out of six:
1 :Valuation Score
3 :Past Performance Score
5 :Financial Strength Score
3 :Future Growth Score
0 :Dividend Score
3 :Overall Score